Influenza A IgA ELISA kit description:

Enzyme immunoassay based on microtiter plate for the detection and quantitative determination
of human IgA antibodies against Influenza A in serum and plasma. Laboratory results can never be the only base of a medical report. The patient history and further tests have to be taken into account.

The influenza infection is an acute feverish virus infection, which principally leads to an illness of
the respiratory tract and appears as an epidemic or pandemic. The infection mostly results from a
droplet infection. The virus spreads from the mucous membrane of the upper respiratory to the
whole bronchial tract. There the virus and its toxin can lead to a serious inflammation of the
bronchial mucosa and a damage of the vessels. After an incubation time of 1 to 3 days the
symptoms appear suddenly: Followed by a fast increase of temperature, often accompanied by
shivering, the catarrhal leading symptom appears, which contribute to the clinical course beside
painful dry cough, tracheitis, laryngitis and frequently a rhinitis and conjunctivitis.
The Influenza viruses form a virus group with principally similar morphological, chemical and
biological features. The types A, B and C were defined, from which many other variants are known.
The determination of the Influenza type (A, B, and C) gives both the clinician and epidemiologist
important indications for further actions. Thus Influenza B often leads to a serious clinical course
and an epidemic spread of the virus. Similarly, during an Influenza A epidemic, the epidemiological
importance and derived measures for the protection of the individual and population primarily stand
in the foreground together with the severity of the clinical symptoms.

The Diagnostic Automation Inc. Influenza A IgA antibody test kit is based on the principle of the
enzyme immunoassay (EIA). Influenza A antigen is bound on the surface of the microtiter strips.
Diluted patient serum or ready-to-use standards are pipetted into the wells of the microtiter plate. A
binding between the IgA antibodies of the serum and the immobilized Influenza A antigen takes
place. After a one hour incubation at room temperature, the plate is rinsed with diluted wash
solution, in order to remove unbound material. Then ready-to-use anti-human-IgA peroxidase
conjugate is added and incubated for 30 minutes. After a further washing step, the substrate (TMB)
solution is pipetted and incubated for 20 minutes, inducing the development of a blue dye in the
wells. The color development is terminated by the addition of a stop solution, which changes the
color from blue to yellow. The resulting dye is measured spectrophotometrically at the wavelength
of 450 nm. The concentration of the IgA antibodies is directly proportional to the intensity of the color.